Recently the Scottish Medicines Consortium (SMC) completed their re-appraisal of ropeginterferon alfa-2b (Besremi) for the treatment of Polycythaemia Vera (PV).
MPN Voice contributed to the process with written submissions, including very valuable testimony from PV patients who are being treated with Besremi, and participation in the SMC Committee meeting to discuss the appraisal of this treatment.
Unfortunately, the SMC have decided that, as things stand, they are not able to recommend this medicine for use by NHS Scotland. Despite this disappointing news, we are very grateful to the patients and volunteers who represented the MPN community throughout the appraisal process and we hope that in due course there will be a further opportunity to achieve a positive outcome for PV patients in Scotland by gaining approval for the use of this treatment.
